Acadia Pharmaceuticals: 3 Different Insiders Have Sold Shares During The Last 30 Days

| About: ACADIA Pharmaceuticals (ACAD)
This article is now exclusive for PRO subscribers.

In this article, I will feature one biotech stock that has seen intensive insider selling during the last 30 days. Intensive insider selling can be defined by the following three criteria:

  1. The stock was sold by three or more insiders within one month.
  2. The stock was not purchased by any insiders in the month of intensive selling.
  3. At least two sellers decreased their holdings by more than 10%.

Acadia Pharmaceuticals (NASDAQ:ACAD) focuses on innovative treatments that address unmet medical needs in neurological and related central nervous system disorders.

Insider selling during the last 30 days

Here is a table of Acadia's insider-trading activity during the last 30 days by insider.

Name Title Trade Date Shares Sold Rule 10b5-1 Current Ownership Decrease In Ownership
Leslie Iversen Chairman Jan 2 60,000 Yes 13,500 shares + 7,277 options 74.3%
Thomas Aasen CFO Jan 2 30,000 Yes 31,348 shares + 90,471 options 19.8%
Laura Brege Director Dec 10 44,117 Yes 0 shares 100%

There have been 134,117 shares sold by insiders during the last 30 days. All these shares were sold pursuant to a Rule 10b5-1 plan.

SEC Rule 10b5-1 is a regulation enacted by the United States Securities and Exchange Commission (SEC) in 2000. The SEC states that Rule 10b5-1 was enacted in order to resolve an unsettled issue over the definition of insider trading, which is prohibited by SEC Rule 10b-5. After Rule 10b5-1 was enacted, the SEC staff publicly took the position that canceling a planned trade made under the safe harbor does not constitute insider trading, even if the person was aware of the inside information when canceling the trade. This staff interpretation raises the possibility that executives can exploit this safe harbor by entering into 10b5-1 trading plans before they have inside information while retaining the option to later cancel those plans based on inside information.

For example, a CEO of a company could call a broker on January 1 and enter into a plan to sell a particular quantity of shares of his company's stock on March 1, find out terrible news about his company on February 1 that will not become public until April 1, and then go forward with the March 1 sale anyway, saving himself from losing money when the bad news becomes public. Under the terms of Rule 10b5-1(b) this is insider trading because the CEO "was aware" of the inside information when he made the trade. But he can assert an affirmative defense under Rule 10b5-1(c), because he planned the trade before he learned the inside information.

In general, it is a safer way for an insider to sell shares pursuant to a Rule 10b5-1 trading plan than without it.

Insider selling by calendar month

Here is a table of Acadia's insider-trading activity by calendar month.

Month Insider selling / shares Insider buying / shares
January 2014 90,000 0
December 2013 59,117 0
November 2013 52,692 0
October 2013 40,000 0
September 2013 248,474 0
August 2013 127,771 0
July 2013 0 0

There have been 618,054 shares sold, and there have been zero shares purchased by insiders since July 2013.


Acadia reported the third-quarter financial results on November 6 with the following highlights:

Revenue $0.2 million
Net loss $10.7 million
Cash $196.2 million


Acadia expects that its cash, cash equivalents and investment securities will be greater than $183 million at December 31, 2013.

Pipeline and upcoming milestones

Acadia's lead product candidate is pimavanserin, which is in Phase III development as a potential first-in-class treatment for Parkinson's disease psychosis.

(Source: Acadia)

Acadia's upcoming milestones include the pimavanserin Parkinson's disease psychosis program NDA submission, which is anticipated near the end of 2014.


Acadia's competitors include AstraZeneca (NYSE:AZN) with Seroquel, Eli Lilly (NYSE:LLY) with Zyprexa, and Pfizer (NYSE:PFE) with Xalatan. Here is a table comparing these companies.

Market Cap: 2.30B 73.75B 55.20B 197.80B
Employees: 26 51,700 38,350 78,400
Qtrly Rev Growth (yoy): -0.93 -0.07 0.06 -0.02
Revenue: 1.49M 26.15B 23.26B 56.25B
Gross Margin: N/A 0.81 0.79 0.81
EBITDA: -32.89M 9.90B 7.26B 24.62B
Operating Margin: -22.15 0.29 0.25 0.32
Net Income: -32.71M 4.64B 4.78B 10.68B
EPS: -0.42 3.71 4.37 3.62
P/E: N/A 15.87 11.69 8.42
PEG (5 yr expected): -2.86 -1.08 -5.21 4.75
P/S: 1,535.81 2.81 2.36 3.51

Acadia doesn't have any approved products yet.

Here is a table of these competitors' insider-trading activities this year.

Company Insider buying / shares Insider selling / shares


PFE 758 1,268,368

Only Acadia has seen intensive insider selling during the last 30 days.


There have been three different insiders selling Acadia, and there have not been any insiders buying Acadia during the last 30 days. All three of these insiders decreased their holdings by more than 10%. Acadia has an insider ownership of 0.10%.

There are eight analyst buy ratings, one neutral rating, and zero sell ratings with an average price target of $25.25. Before entering short Acadia, I would like to get a bearish confirmation from the Point and Figure chart. The two main reasons for the proposed short entry are bearish analyst price targets, and the intensive insider-selling activity.

Disclosure: I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.